Oncology co NovoCure to lay off 200

Novocure  credit: Nasdaq OMX
Novocure credit: Nasdaq OMX

The company, which has developed a novel therapy for solid tumors using electric fields, has announced a strategic restructuring program.

Oncology company NovoCure (Nasdaq: NVCR), which has developed a novel therapy for solid tumors using electric fields, has announced a strategic restructuring program to save $60 million in operating expenses. The program includes laying off 200 employees, 13% of the workforce, although there will only be a few layoffs in the company's Israel development center. "Decisions like these are deeply personal and challenging, because of the impact on our employees and their families," said NovoCure CEO Asaf Danziger. "To those departing NovoCure, I want to express my sincere gratitude for your hard work. Your contributions have influenced the lives of many cancer patients and your legacy will forever be intertwined with NovoCure."

NovoCure is not in any immediate cash-flow crisis with $921 million cash in the company's coffers, while commitments amount to $127 million and long-term debt is $567 million. The company says it prefers to focus its resources on financing future growth.

NovoCure became an Israeli success story after developing its novel GBM treatment for brain tumors. The company's technology was invented by Prof. Yoram Palti from the Technion - Israel Institute of Technology after his retirement, based on his PhD thesis, which he always hoped to development further when he had more time. The company's value soared on the promise of also being applicable to other more common types of cancers and at its peak in June 2021, NovoCure had a market cap of $22.9 billion.

The biotech bubble burst

In 2021, the biotech bubble burst on Nasdaq and by 2022 NovoCure's market cap had fallen to $8 billion. Following clinical trials results, the company's market cap has fallen in recent months to just $1.33 billion, 94% below its peak.

Such sharp falls in biotech development companies are usually related to failed clinical trials and not having any assets but that is certainly not the case with NovoCure. In the third quarter of 2023, the company recorded revenue of $127 million, an impressive amount for an independent medical device company originating in Israel. But revenue was down 3% from the corresponding quarter of 2022, largely due to difficulties in obtaining indemnity for patients from insurance companies.

To deal with saturation in its existing markets, especially the GBM market, NovoCure is expanding globally. In the third quarter, 68% of the company's revenue came from the US, and the rest from Germany, Japan and China. In the third quarter NovoCure recorded a loss of $49 million, due to high development and marketing costs.

But the share price didn't fall for that reason. The market realized that brain cancer was a small indication to prove feasibility, while the more exciting indications are, for example, common NSCLC type lung cancer. NovoCure has reported trial success in this type of metastatic cancer, and is now preparing to launch the product, after hoping to receive FDA approval in 2024.

However, in May, doctors at the ASCO cancer conference claimed that although the trial achieved its goals and may even be approved by the FDA, by the time the trial ends these goals have already become obsolete, and it is not certain that the results will be convincing enough for doctors to adopt the technology. This is one of the leading reasons for the stock's decline. In addition, in August the company published poor results in an ovarian cancer treatment trial.

NovoCure's current cuts are not in the NSCLC sector. On the contrary, the company plans focusing resources on the commercial launch of this product, if it is approved. In addition, it expects results in 2024 in two other clinical trials - one for treating NSCLC's brain metastases and the second is for treating pancreatic cancer, which could be an even more major market for the company.

Published by Globes, Israel business news - en.globes.co.il - on December 11, 2023.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2023.

Novocure  credit: Nasdaq OMX
Novocure credit: Nasdaq OMX
Eon founders credit: Eon Investors press Eon to raise money at $2.5b valuation

The Israeli cloud backup company saw its valuation soar last year in three financing rounds from $215 million to $1.4 billion.

Aryon founders credit: Nadav Margalit Israeli cloud security co Aryon raises $9m

The Tel Aviv-based company has developed a cloud security enforcement platform, which pioneers a proactive approach that aims to transform cloud security by preventing cloud risks before they emerge.

IATA CEO Karin Mayer Rubinstein credit: Michael Franco IATI optimistic life sciences recovery will continue

85% of the senior figures in venture capital funds in Israel's biomed sector see investments by companies and foreign funds increasing in 2025 compared with 2024.

Average wage in Israel credit: Shutterstock Rita Kapitulski Average wage in Israel rose 5.1% in 2024

The average wage of an Israeli employee rose by 5.1% in 2024, compared with 2013, the Central Bureau of Statistics reports.

Eilat house near the sea credit: Amram Avraham Investor buys Eilat house near sea for NIS 5.8m

A six-room, 164 square meter house with a 362 square meter yard was sold recently to an Israeli from the center of the country.

European leaders' defense summit in London, March 2025  credit: Reuters/Javad Parsa Israeli defense cos seen gaining as Europe rearms

Not only are Israeli systems highly respected, but Israeli companies are well adapted to working in Europe.

Bank Leumi branch credit: Eyal Izhar Leumi posts largest ever bank profit

Bank Leumi earned a profit of NIS 9.8 billion in 2024, 40% more than in 2023.

Medical research  credit: Shutterstock Boston Scientific buys Israeli medical device co SoniVie

The US medical device company will pay up to $540 million for the Rehovot-based intravascular ultrasound device developer for treating high blood pressure.

Dina Ben Tal Ganancia  credit: Guy Kushi & Yariv Fein El Al agrees to shoulder higher security costs

In exchange for lowering the government's security spending burden, El Al expects state permission to distribute dividends.

Playtika head office in Herzliya Credit: Eyal Izhar Playtika stock sinks to all-time low

The Israeli mobile games developer's share price has fallen over 80% since its Wall Street IPO four years ago.

Ronit Harel Ben Zeev credit: Osnat Rom S&P Maalot Israel CEO: Capital market needs more women

Ronit Harel Ben Zeev talks to "Globes" about she came to work at the Tel Aviv Stock Exchange, the Israeli economy and S&P Maalot.

Building work on Sarona Hotel credit: Shutterstock Work moves slowly ahead on one of Israel's biggest hotels

After years of delays, construction work resumed several months ago on the 800-room, 47-floor Sarona Hotel in Tel Aviv.

New car deliveries in Israel credit: Shutterstock New car deliveries in Israel hit five year low

Deliveries of gasoline, hybrid and plug-in vehicles were led by Hyundai with 9,251 deliveries since the beginning of the year.

Yadin Antebi  credit: Jonathan Bloom Hapoalim posts record annual profit, sets targets

Bank Hapoalim expects to post a profit of NIS 8.5-9.5 billion in each of the years 2025 and 2026, but expresses concern about the real estate sector.

Venture capital credit: Shutterstock Andreessen Horowitz boosting Israel VC investments

According to the IVC-Gornitzky-KPMG-Israel Innovation Authority investors report for 2024, the US venture capital fund has become one of the most active foreign investors in Israel.

Wiz Sarona offices inset Assaf Rappaport credit: Wiz Omer Hacohen Wiz leases five floors in renovated Sarona building

Exclusive: The Israeli cloud security company is leasing 5,500 square meters of space in a preserved Tel Aviv Templar building.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018